SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

Oppenheimer Maintains Outperform on Allogene Therapeutics, Raises Price Target to $50

Oppenheimer maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and raises the price target from $44 to $50.

Benzinga · 05/14/2020 12:53

Oppenheimer maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and raises the price target from $44 to $50.